Vision redemption: Self-reporting AIEgens for combined treatment of bacterial keratitis

Biomaterials. 2021 Dec:279:121227. doi: 10.1016/j.biomaterials.2021.121227. Epub 2021 Oct 22.

Abstract

Bacterial keratitis (BK) is one of the most commonly leading causes of visual impairment and blindness worldwide, and suffers the risk of drug-resistant infections due to the abuse of antibiotics. Herein, we report a cationic diphenyl luminogen with aggregation-induced emission called IQ-Cm containing isoquinolinium and coumarin units for theranostic study of BK. IQ-Cm has no obvious cytotoxicity to mammalian cells below a certain concentration, and could preferentially bind to bacteria over mammalian cells. IQ-Cm can be used as a sensitive self-reporting probe to rapidly discriminate live and dead bacteria by the visual emission colors. The intrinsic dark toxicity to bacteria and generation of reactive oxygen species under light irradiation endow IQ-Cm with excellent antibacterial activity in vitro and in BK rabbit models infected with S. aureus. The present study provides a sensitive and efficient theranostic strategy for rapid discrimination of various bacterial states and the combined treatment of BK based on the intrinsic dark antibacterial activity and photodynamic therapy effect.

Keywords: Aggregation-induced emission; Bacteria killing; Keratitis treatment; Photodynamic therapy; Self-reporting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Bacteria
  • Keratitis* / drug therapy
  • Photochemotherapy*
  • Rabbits
  • Staphylococcus aureus

Substances

  • Anti-Bacterial Agents